News

Moderate THST linked to improved survival in thyroid cancer

Publish date: November 10, 2014

 

AT THE ATA ANNUAL MEETING

References

The registry has received support from Genzyme and Pfizer. Dr. Carhill reported having no financial disclosures.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Pages

Recommended Reading

Pituitary tumor size not definitive for Cushing's
MDedge Endocrinology
Prolactin measure didn’t help localize pituitary adenoma
MDedge Endocrinology
New chemo regimen is active against recalcitrant neuroendocrine tumors
MDedge Endocrinology
Growth hormone levels predict postsurgical acromegaly remission
MDedge Endocrinology
Lobectomy suffices for surgery of small papillary thyroid cancers
MDedge Endocrinology
Pasireotide decreases incidence of postoperative fistula
MDedge Endocrinology
Experimental lenvatinib extends PFS in iodine-refractory relapsed thyroid cancer
MDedge Endocrinology
Tests pinpoint primary sources of neuroendocrine bowel, pancreatic metastases
MDedge Endocrinology
Anticoagulants sharply increase hematoma risk after thyroid, parathyroid surgery
MDedge Endocrinology
No survival benefit of RAI seen in early-stage thyroid cancer
MDedge Endocrinology